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Background: The neuropsychiatric syndrome mild behavioral impairment (MBI)
describes an at-risk state for dementia and may be a useful screening tool for sample
enrichment.We hypothesized that stratifying a cognitively normal sample onMBI sta-
tus would enhance the association between genetic risk for Alzheimer’s disease (AD)
and cognition.
Methods:Data from 4458 participants over age 50 without dementia was analyzed. A
cognitive composite score was constructed and the MBI Checklist was used to strat-
ify those with MBI and those without. Polygenic scores for AD were generated using
summary statistics from the IGAP study.
Results: AD genetic risk was associated with worse cognition in the MBI group but
not in the no MBI group (MBI: β = –0.09, 95% confidence interval: –0.13 to –0.03,
P = 0.002, R2= 0.003). The strongest association was in those with more severe MBI
aged≥65.
Conclusions:MBI is an important feature of aging; screening on MBI may be a useful
sample enrichment strategy for clinical research.
KEYWORDS
Alzheimer’s disease, cognition, mild behavioral impairment, neuropsychiatric symptoms, poly-
genic score
1 BACKGROUND
Worldwide, the number of people with dementia is expected to rise to
150 million by 2050. Recent years have been marked by a number of
high-profile failures of disease-modifying therapies and it is nowwidely
recognized that identification of people in the very earliest stages of
disease is a key priority for clinical trials of new treatments, and ulti-
mately for clinical practice.1 Genetic predictors of cognitive decline
and dementia have been the subject of considerable focus in recent
years. These predictors include not only apolipoprotein E (APOE) sta-
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tus but also polygenic risk scores (PRS). PRS are the sumof Alzheimer’s
disease (AD) risk alleles carried by an individualweightedby effect size,
and therefore capturemore genetic risk thanAPOE alone. The ultimate
goal of this work is the identification of a low-cost early marker of neu-
rodegenerative disease. As an important first step, numerous studies
have shown that AD genomic markers predict AD and mild cognitive
impairment (MCI) case/control status, as well as progression to AD
among MCI cases.2–7 However, the association between AD genetic
risk and objectively measured cognition in non-dementia samples is
less consistent.8–15 There are a number of methodological differences
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that likely explain these discrepancies, including the sensitivity of cog-
nitive outcomemeasures and the number of risk alleles included in PRS
calculation. One additional challenge is the complex etiology of cogni-
tion in older adults, which is not solely accounted for by genetic risk
for neurodegeneration or neuropsychological profile. Because of the
ease and low cost of genetic analysis, and promising initial findings, it
is logical to explore additional strategies that may enhance sensitivity
in older samples.
Previous research has shown that the association between APOE
ε4 and cognition is strongest in older adults, one possible implica-
tion being that there are more people in older samples whose cogni-
tive profile is linked to early neurodegeneration.14 One study found
that stratification based on amyloid beta (Aβ)-positive positron emis-
sion tomography (PET) scans unmasked an association between AD
PRS and poorer memory and executive function.12 That neuropatho-
logical markers of AD moderate the association between AD genetic
risk and neuropsychological measures is not surprising, but does offer
proof of principle of sample enrichment, informing our study. To add
value to a genetic screen, such sample enrichment should be low
cost and scalable to large populations. There is evidence that later-
life emergent neuropsychiatric symptoms (NPS), described by the val-
idated syndrome mild behavioral impairment (MBI), may represent
such a screening tool. MBI is a neurobehavioral syndrome proposed
by an Alzheimer’s Association consensus group to describe a risk
state for cognitive decline and dementia to facilitate earlier demen-
tia detection.16 The MBI syndrome covers late-life–emergent apathy,
mood/anxiety symptoms, impulse dyscontrol, social inappropriateness,
and psychotic symptoms, and is common and easily measured in the
general population.17 Moreover, MBI is associated with progressive
cognitive decline in individuals without significant cognitive impair-
ment, a shorter time to dementia, and has recently been shown to asso-
ciate with dementia biomarkers including PET amyloid, tau, and neuro-
filament light in cognitively normal samples.18–26 On the basis of this
evidence, MBI is an attractive candidate tool to enrich samples with
individuals at greater risk of dementia, but to our knowledge no stud-
ies have explored how stratification onMBI influences the relationship
between genetic risk for AD and cognition. In this study we aimed to
elucidate whether stratifying a cognitively normal sample on the pres-
ence of MBI symptoms affected the association between genetic risk
for AD and general cognitive ability. We hypothesized AD genetic risk
would be associated with poorer cognition and that this relationship
would be strongest among people withMBI symptoms.
2 METHODS
2.1 Participants
All participantswere drawn from the PROTECT study (Research Ethics
Committee reference number 13/LO/1578). PROTECT is a UK-based
online participant registry that tracks the cognitive health of older
adults. Inclusion criteria for enrolling in PROTECT are (1) ≥50 years
old, (2) no diagnosis of dementia, and (3) access to a computer and
RESEARCH INCONTEXT
1. Systematic review: we reviewed the literature using a
PubMed and Google Scholar search. There is increas-
ing evidence from clinical risk and biomarker studies
that mild behavioral impairment (MBI) represents an at-
risk state for dementia and may be the first manifesta-
tion of neurodegenerative disease. It is therefore possi-
ble that MBI screening could represent a useful sample
enrichment strategy for clinical studies and possibly tri-
als. We tested this hypothesis by examining the relation-
ship between genetic risk for Alzheimer’s disease (AD)
and cognition in people withMBI and in those without.
2. Interpretation: We show for the first time that stratifica-
tion onMBI symptoms led to an enhanced signal between
genetic risk for AD and cognition in a cognitively normal
sample.
3. Future directions: We propose that screening on MBI
symptoms may be a novel strategy for enriching samples
for individuals at risk of dementia. Our findings and study
design provide a framework for further investigation of
this application ofMBI assessment.
internet. The sample used in this study is a subset of PROTECT study
participants who also provided a saliva sample for genotyping, com-
pleted cognitive testing, and had a proxy informant available to com-
plete the MBI Checklist (MBI-C; further detail is presented below).
Specifically, genome-wide genotype data for 9146 PROTECT partic-
ipants was available for analysis in this study. Of these, clinical data
required for this analysis from self-report and proxy informant was
available from 4458 people. The difference in numbers providing DNA
and those with required clinical data is due to the MBI-C being com-
pleted by proxy informant, and nomination of a proxy is optional.Writ-
ten informed consent was obtained from all participants and proxy
informants. The authors assert that all procedures contributing to this
work comply with the ethical standards of the relevant national and
institutional committees on human experimentation andwith the Dec-
laration of Helsinki 1975, as revised in 2008.
The following demographic data, which are routinely collected dur-
ing PROTECT, were used in this analysis as covariates: age, sex, edu-
cation level (school until 16, school until 18, vocational qualification,
undergraduate degree, post-graduate degree, and doctoral degree)
and employment status (full time, part time, self-employed, retired, and
unemployed).
2.2 Assessment of cognition
Cognitive performance was assessed via a battery of four tests
(Table 1). Individual performance across cognitive tests is known to be
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TABLE 1 Description of the cognitive battery used
Test Description Cognitive domain
Paired associates learning A series of objects appear in the cells on screen. The participant is instructed
to remember the cell in which the object appears.When an object appears
at the bottom center, the participant is instructed to click on the cell in
which they recall seeing that object.
Visual workingmemory,
learning
Digit span Using a ratchet-style approach in which each successful trial is followed by a
new sequence that is 1 digit longer than the last and each unsuccessful trial
is followed by a new sequence that is 1 digit shorter than the last.
Workingmemory
Self-ordered search A series of boxes are present on the screen; one of the boxes will contain a
diamond. The participant selects each box until they locate the diamond.
The diamond is then placed in another box and again the participant must





Verbal reasoning A sentence is displayed at the bottom of the screenwhile a square and a
circle are displayed above. The participant needs to respond true or false
as to whether the sentence correctly describes the configuration of the
circle and square.
Verbal reasoning
correlated, and for this study we analyzed a general cognitive compos-
ite based on factor analysis of the battery. This latent construct is a
well-documented feature of cognition.27 To capture general cognitive
ability in this sample, a composite score was calculated by computing
the first unrotated principal component of the cognitive battery. The
variance in total cognitive test score explained by the first principal
component was 48.7% and the factor loadings were 0.53 (paired asso-
ciated learning), 0.5 (digit span), 0.46 (self-ordered search), and 0.50
(verbal reasoning). This finding is comparable to recent reports in an
analysis of more than 300,000 individuals across multiple cohorts.28
In the present study, higher cognitive composite score was associ-
ated with a lower likelihood of Informant Questionnaire on Cognitive
Decline in the Elderly (IQCODE) score >3.3, which indicates a nega-
tive change in cognition over 10 years via a questionnaire observed
by a proxy informant (odds ratio [OR] = 0.84, 95% confidence inter-
val [CI]: 0.78–0.91 P < 0.001, controlling for age, sex, and education).
It was also associated with greater impairment in instrumental activi-
ties of daily living (IADL) asmeasured by theMinimumData Set–Home
Care IADL scale (β = 0.156, 95% CI: 0.06–0.25 P = 0.001), providing
validation that the cognitive construct is meaningful in the context of
our sample.29,30
2.3 Assessment of neuropsychiatric symptoms in
the MBI framework
Neuropsychiatric symptoms were operationalized in the MBI frame-
work using the MBI-C. The MBI-C is a validated tool designed specif-
ically for capturing MBI symptoms and, in this study, was completed
by a proxy informant who knew the participant well for at least 10
years.17,31–33 The scale consists of 34 questions covering the full range
of MBI domains (apathy, mood/anxiety symptoms, impulse dyscon-
trol, social inappropriateness, and psychotic symptoms). Each ques-
tion is rated on a scale of 0 (not present) to 3 (severe). The MBI-
C mandates that a symptom must be present for at least 6 months
and represent a change from longstanding behavior to be rated as
present. This approach facilitates differentiation of MBI symptoms
from transient neuropsychiatric symptoms, and reactive conditions
due to medical and environmental precipitants and life stressors to
better reflect the new onset symptomatology seen in neurodegen-
erative disease.34 In this study, participants were classified as hav-
ing any symptoms of MBI (MBI-C total score >0) or having no MBI
symptoms (MBI-C total score = 0) due to the strong positive skew
of the MBI-C data (i.e., ≈50% of respondents can be expected to
score zero).17 Any participants with the following medical conditions
were excluded (all derived from self-report responses to the ques-
tion “Have you ever been diagnosed with one or more of the fol-
lowing even if you don’t have it currently?”): mild cognitive impair-
ment (n = 11), stroke (n = 72), Parkinson’s disease (n = 11). This was
done tominimize confounding associatedwith potential dementia syn-
dromes and to better reflect the Alzheimer’s Association MBI diag-
nostic criteria stipulation that symptoms cannot be better explained
by a pre-existing medical or psychiatric condition.16 Self-reported life-
time history of psychiatric diagnoses was also recorded (depression,
mania/bipolar/manic depression, anxiety/generalized anxiety disorder,
panic attacks, eating disorders, autism/Asperger’s/autistic spectrum
disorder, attention deficit disorder, schizophrenia/other psychotic ill-
nesses, personality disorders, and social anxiety/phobia, n = 1515).
In addition to lifetime self-reported diagnosis we also captured cur-
rent depressive symptom status using the Patient Health Ques-
tionnaire 9 (PHQ-9); here we dichotomized participants into who
scored ≥10 on the PHQ-9 (n = 128) and those scoring <10, which
has good sensitivity and specificity for a current major depressive
episode.35
The binary coding of the MBI-C is supported by recent data show-
ing that in cognitively normal people, a score >0 on the MBI-C (i.e.,
the presence of any symptoms of any severity) was associated with
worse cognitive performance (both at baseline and over 1 year) on
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a range of tests, with a score of >8 being associated with the worst
performance.19
2.4 Genotyping, genetic data quality control, and
AD polygenic risk score calculation
Saliva samples were collected by post and DNA extract by the
National Institute for Health Research South London and the Maud-
sley National Health Service Biomedical Research Centre. Genotyp-
ing was done used the Illumina Global Screening Array with custom
content (includingdirectly genotyped singlenucleotidepolymorphisms
[SNPs], rs429358 and rs7412, to determine APOE status). The total
numbers of participants in the combined genotyped data for the whole
PROTECT study was 9146. Genotype quality control (QC) was per-
formed on all of these individuals but only those with MBI and cogni-
tive data were included in the association analysis. Iterative filtering
for call rate at 98% completeness (for individuals and SNPs) resulted in
the exclusion of 84 samples, after which 9062 remained. In the filtered
data relatedness was estimated using KING 2.2.3, followed by extrac-
tion of a list of individuals that contained no pairs of individuals with
a first-, second-, or third-degree relationship.36 Variants with Hardy–
Weinberg equilibrium P-value < 0.00001 were excluded. Individuals
whose sex estimated in plink did not match that reported by the study
participants were excluded. Principal components (PCs) were calcu-
lated for the unrelated subset of the data using EIGENSOFT 6.1.4 after
pruning using awindow size of 1500bases per 150 kb and an r-squared
of 0.2.37,38 Variants in high linkage disequilibrium regions and non-
autosomal regions were also excluded. K-means clustering (assuming
four distinct clusters) was used on the first two derived PCs to define
a cluster of European ancestry individuals. PCs were then recalcu-
lated for the cluster of individuals of European ancestry, with outlier
individuals removed by EIGENSOFT if exceeding a sigma threshold of
30. Finally, individuals with excess heterozygosity (unusual patterns of
genome-wide heterogeneity) calculated using the ibc function in plink
v1.90were excluded.39 The total number of individuals excludedwhen
removing those that were either related, of non-European ancestry,
of mismatched sex, outliers in the PC calculation, or detected to have
excess heterozygosity was 790 given an original sample size of 9062
participants.
International Genomics of Alzheimer’s Project (IGAP) AD genome-
wide association study (GWAS) summary statistics were used to calcu-
late PRS using PRSice v2.2.12.40,41 Directly genotyped data was used
for the PRS calculation and the total number of variants available after
QCwas 630,180.
Previous data suggest a wide range of inclusion thresholds for AD
PRS calculation, from only genome-wide significant SNPs to many
thousands of SNPs.2,3,8–15 In this study, we opted for two AD GWAS
SNP inclusion thresholds (PT). The first, 5× 10–8 (22 SNPs after clump-
ing), was chosen because it was the most strongly associated with a
family history of AD (defined as self-reported number of parents with
AD) in this sample (β= 0.05, 95%CI: 0.03–0.06, P< 0.001) and the sec-
ondwas all IGAP SNPs (i.e., PT= 1, 83,540 SNPs after clumping).
2.5 Statistical analysis
PRS were standardized to a mean of 0 and standard deviation of 1
before analysis. Regression coefficients thus represent unit increase
in cognitive composite score per one standard deviation increase in
PRS. The association between AD genetic risk and cognition was first
tested by linear regression in the whole sample at both PT. The sam-
ple was then stratified by MBI status and the dependent variable of
cognitive composite was analyzed by linear regression with AD PRS
and age, sex, education level, employment status (dummy coded), life-
time history of psychiatric diagnosis, PHQ-9 grouping (≥10 and <10),
and the first six ancestry PCs as covariates. The inclusion of psychi-
atric history and PHQ-9 grouping, thus, allows us to bemore confident
that findings are the result of MBI specifically and not confounded by
MBI-Cmeasurements capturing concurrent psychiatric disorders. Sub-
sequent identicalmodelswere run that also controlled forAPOE ε4 sta-
tus to assess the independent effect of non-APOE SNPs in the PRS. The
proportion of variance explained by the PRS was represented by R2 of
themodelwithonly covariates subtracted from theR2 of the fullmodel.
Regression assumptions were checked by examining residual plots and
checking for outliers. Given that the two AD PRS are not independent,
and a Bonferroni correction would therefore be overly conservative, a
family-wise error rate of 0.025 was applied (to reflect tests on the two




After medical history exclusions, data from 4458 participants were
available for analysis. Participant characteristics by MBI group are
shown in Table 2. There was no difference in age, sex, or education
level between the MBI and no MBI strata but, as expected, the MBI
group did have a lower cognitive score. There was a slightly higher
proportion of retired people among those in the no-symptom group
compared to the MBI symptoms group (60% vs. 56%) and more peo-
ple with a history of psychiatric conditions or PHQ-9≥10 also hadMBI
symptoms.
3.2 Relationship between AD PRS, cognition and
MBI
In the whole sample analysis adjusting for covariates, AD PRS at PT= 1
was associated with a lower mean cognitive composite score (β = –
0.07, 95%CI: –0.11 to–0.03,P<0.001,R2=0.002) andmodestly at the
more conservative PRS at PT= 5 × 10–8 (β= –0.04, 95%CI: –0.8–0.00,
P=0.03,R2=0.001). Accordingly, the rest of the analysiswas only con-
ducted on ADPRS at PT= 1.
A plot of the relationship between adjustedmean cognitive compos-
ite score andADPRSadjusted for covariates is shown inFigure1. In the
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TABLE 2 Participant characteristics byMBI group
MBI group
No symptoms (MBI-C= 0) MBI symptoms (MBI-C>0) P
N (%) 1865 42 2593 58
Age (mean, sd) 63.6 6.7 63.5 7.2 0.9
Sex (n, %)
Female 1423 76 1999 77 0.78
Male 442 24 594 23
Education level (n, %)
Secondary education 202 11 335 13 0.14
Post-secondary education 201 11 324 12
Vocational qualification 364 20 475 18
Undergraduate degree 690 37 922 36
Post graduate degree 328 18 442 17
Doctoral degree 80 4 95 4
Employment status (n, %)
Full time 263 14 390 15 0.003
Part time 262 14 427 16
Self-employed 202 11 248 10
Retired 1110 60 1458 56
Unemployed 28 2 70 3
Life-time history of any psychiatric diagnosis
No 1356 73 1587 61 ≤0.001
Yes 509 27 1006 39
PHQ-9
≤10 1850 99 2480 96 ≤0.001
≥10 15 1 113 4
Cognitive composite (mean, sd) 0.14 1.4 –0.06 1.4 <0.001
Note: Cognitive composite is the first unrotated principal component derived from scores on paired associates learning, digit span, self-ordered search, and
verbal reasoning.
Abbreviations: MBI, mild behavioral impairment; MBI-C, mild behavioral impairment Checklist; PHQ-9; Patient Health Questionnaire 9; sd, standard devia-
tion.
analysis stratified byMBI symptoms after adjusting for covariates, the
associationbetweenADgenetic risk and cognitionpersistedbutonly in
thosewithMBI symptoms (β=–0.09, 95%CI: –0.13 to–0.03,P=0.002,
R2=0.003, Table 3). In thosewith noMBI symptoms therewas no asso-
ciation betweenADgenetic risk and cognition (Table 3). Controlling for
APOE did not change the direction of associations, though there was a
decrease in proportion of variance explained (whole sample: β= –0.06,
95% CI: –0.10 to –0.02, P = 0.003, R2= 0.002; MBI symptoms: β = –
0.07, 95%CI: –0.12 to –0.02., P= 0.01, R2= 0.002).
3.3 Sensitivity analyses
This analysis was conducted post hoc so should be considered
exploratory. Inourprimaryanalysisweadoptedabinary coding forMBI
symptoms (nonevs. any) becauseof evidence that even individualswith
low-level symptoms have an increased risk of cognitive decline. There
are no accepted cut points on theMBI-C in cognitively normal commu-
nity samples so we examined the association between AD PRS, cogni-
tive impairment, andMBI using anMBI-C cut point of≥6 (n=979). The
association observed in the main analysis was sustained for those with
MBI symptoms at this more conservative MBI-C cut point (β = −0.10,
95% CI: −0.18 to −0.02, P = 0.01, R2= 0.005, Table 3). To illustrate
this relationship, adjusted mean cognitive composite score by AD PRS
stratified by MBI-C using the higher threshold split is plotted in Fig-
ure 2. Finally, because of prior evidence showing that AD PRS is a
stronger predictor of cognition in older people we examined the same
relationship in those aged 65 or over (n = 369).42 This analysis is plot-
ted in Figure 3 and shows a further strengthening of the relationship
between AD PRS and cognition in those with an MBI-C score ≥6, with
proportion of variance explained rising from 0.005 to 0.02 (β = −0.20,
95% CI: −0.34 to −0.06, P = 0.005, R2= 0.02, Table 3). The increase in
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F IGURE 1 Relationship between Alzheimer’s disease (AD) polygenic risk score (PRS) and cognitive composite. Fitted lines are adjusted linear
regression of PRS on cognitive composite for nomild behavioral impairment (MBI) symptoms andMBI symptom groups (shaded area is 95%
confidence interval)
TABLE 3 Results of linear regression of AD PRS on cognitive composite at PT= 1 (83,540 SNPs)
Group β L 95%CI U 95%CI P R2
Whole sample −0.07 −0.11 −0.03 <0.001 0.002
MBI symptoms (MBI-C> 0) −0.09 −0.13 −0.03 0.002 0.003
NoMBI symptoms (MBI-C= 0) −0.05 −0.11 0.01 0.09 0.001
Sensitivity analysis
MBI symptoms (MBI-C≥6) −0.10 −0.18 −0.02 0.02 0.005
MBI symptoms (MBI-C≥6), aged≥65 −0.20 −0.34 −0.06 0.005 0.02
Notes: Analysis controlled for age, sex, education, employment status, lifetime psychiatric diagnosis, PHQ-9 group, and the first six ancestry principal compo-
nents.
Beta coefficients represent unit of increase in cognitive composite score per 1 standard deviation increase in PRS.
Abbreviations: AD, Alzheimer’s disease; CI, confidence interval; MBI, mild behavioral impairment; PHQ-9; Patient Health Questionnaire 9; PRS, polygenic
risk scores; SNP, single nucleotide polymorphism.
variance explained was not simply attributable to the older age cutoff;
the R2 in all participants aged≥65was comparable to all that of all par-
ticipantswithMBI-C≥6 (β=−0.08, 95%CI:−0.14 to−0.02, P= 0.009,
R2= 0.004).
4 DISCUSSION
To our knowledge these findings are the first demonstration that sam-
ple stratification on neuropsychiatric symptoms (here assessed in the
MBI framework) may identify a subset of the cognitively normal pop-
ulation in which a stronger relationship between genetic risk for AD
and cognition exists. As such our findings point to MBI-C screening
as a potential sample enrichment tool as well as suggesting potential
confounding by unmeasured neuropsychiatric symptoms in studies of
AD genetic risk in cognitively normal samples. The association was
present in our study using a PRS based on all available SNPs from AD
GWAS (PT= 1); was present even after controlling for psychiatric diag-
noses and PHQ-9 score; and remained after controlling for APOE sta-
tus, albeit with a diminished variance explained. As expected, we con-
clude that APOE is driving some of the signal observed in this study,
consistent with previous reports, but that non-APOE SNPs also play
a role in late-life cognition. More broadly, our findings from this sam-
ple, which is independent from previous reports, support a role for AD
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F IGURE 2 Relationship between Alzheimer’s disease (AD) polygenic risk scores (PRS) and cognitive composite. Fitted lines are adjusted linear
regression of PRS on cognitive composite for nomild behavioral impairment (MBI) symptoms,MBI Checklist (MBI-C) 1—6, andMBI-C≥6 groups
(shaded area is 95% confidence interval)
F IGURE 3 Relationship between Alzheimer’s disease (AD) polygenic risk scores (PRS) and cognitive composite in the subset of the sample
aged≥65. Fitted lines are adjusted linear regression of PRS on cognitive composite for nomild behavioral impairment (MBI) symptoms,MBI
Checklist (MBI-C) 1—6, andMBI-C≥6 groups (shaded area is 95% confidence interval)
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genetic risk, beyond APOE, in cognition among older adults without
dementia, an important finding as there is not unanimity in previous
literature.8−11,13−15
A recent well-phenotyped large study of older adults found that an
AD PRS that included all SNPs (PT= 1) was not associated with cogni-
tion in adults but APOE was.14 Genetic risk for AD has been shown to
be pleiotropic but it is notable that a previous study found the effect
of APOE ε4 on cognition to be stronger in older adults relative to ear-
lier in life.14,42 Older samples are more likely to contain a larger pro-
portion of individuals in prodromal or preclinical disease so a stronger
effect of AD PRS could be reasonably expected. Similarly, we propose
that stratifying on MBI, even among cognitively normal older adults,
has the same effect and defines a cognitive phenotype that is “closer”
to AD. This, in turn, would create better power to detect associations
with those AD SNPs with smaller effect sizes, thus explaining the dis-
crepancy between our finding and this other recent work.
The notion that MBI (i.e., late-life neuropsychiatric symptoms) may
be an early marker of dementia is somewhat counterintuitive for a
group of diseases that are primarily conceptualized as cognitive disor-
ders. This cognocentric approach does not necessarily reflect the his-
tory of AD. Auguste D., the index patient described by Alois Alzheimer,
presented to hospital with emotional dysregulation and suspicious-
ness, followed by cognitive decline.34,43–45 Several longitudinal studies
supportMBI emerging in advance of cognitive symptoms or increasing
risk of incident cognitive decline and dementia.18,20,21,46,47 The distinc-
tion betweenMBI andother neuropsychiatric symptoms as risk factors
versus early markers has been a topic of recent debate.48,49 However,
new data in cognitively normal people showing that MBI symptoms
are associated with higher Aβ burden,23 tau deposition,26 and faster
accumulation of neurofilament light50 support the view of MBI as an
early clinical marker. The implication is therefore that stratification on
MBI symptoms enriches samples for individualswith preclinical or pro-
dromal disease, creating a more etiologically homogenous sample; this
hypothesis is strengthened by our post hoc analysis showing evidence
of a stronger association in thosewithmore severeMBI symptomswho
are aged 65 or over. Deeper phenotyping including imaging and longi-
tudinal follow-upwith detailed neuropsychology and clinical outcomes
will be required to confirm this hypothesis, which could have important
implications for clinical trials in which cohort heterogeneity has been
identified as amajor concern.51
The operationalization of MBI is worth some discussion. A key
strength of this study is the controlling of pre-existing psychiatric con-
ditions and use of the specific MBI-C tool, which has been validated
in cognitively normal samples,17 both of which provide more confi-
dence that our findings are due to later-life emergent mild NPS rather
than longstanding clinically significant psychiatric diagnoses. However,
establishing appropriate cut points on the MBI-C is a matter of ongo-
ing research. Our findings, including our post hoc analysis, and those
of others suggest that relatively mild symptoms are important to con-
sider and that the likely optimal cut point on theMBI-C for case ascer-
tainment would lie somewhere between 2 and 8. This is supported by
previous research showing that low-level symptoms of MBI as well as
more severe symptoms are associated with cognitive decline in cogni-
tively normal individuals.19 Relating to this, a limitation to our study is
the proxy completion of MBI-C via remote questionnaire completion,
which could have led to somemisclassifications, although raters in this
studywere required tohaveknown theparticipant for at least 10years.
Other limitations include the over-representation of women andmore
highly educated people in our sample and, aswithmost genetic studies,
these results may not be generalizable to non-European ancestry pop-
ulations.We note our sample size is relatively small compared tomuch
of the wider genetic literature and replication in independent cohorts
is needed. In particular,wewouldnot rule out aneffect ofADPRS in the
no MBI symptom group, but our data would suggest that this effect is
weaker. The lack of association could bedue to power as theMBI symp-
toms group was larger. However, it is worth noting that in our sensitiv-
ity analysis using amore stringent cut point (MBI-C≥6) therewere925
people in the MBI group, approximately half that of the no-symptoms
group. At present we are not aware of any other large cohort studies
that use the MBI-C; however, we would argue that our findings, along
with the practical advantages of the MBI-C (it is freely available and
quick to complete) provide a strong case for the wider adoption of the
scale, which will allow important follow-upwork to take place.
In summary, this study lends further support to the growing
evidence base that later life emergent neuropsychiatric symptoms
describe an at-risk state for incident cognitive decline and dementia,
and can be the index manifestation of dementia for some. Our find-
ings also support the case for using MBI as a sample enrichment tool
for biomarker studies and clinical trials targeting at-risk individuals.
The enrichment approach is inexpensive, simple, and scalable, and can
decrease cost and improve enrolment efficiency of dementia clinical
trials. Deeper phenotyping of these groups including neuroimaging and
longitudinal monitoring of clinical outcomes is now essential.
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